Akums Drugs & Pharmaceuticals Ltd. has fully restored operations at its Haridwar manufacturing sites to 100% capacity as of May 18, 2026. This follows a four-day disruption that caused a delay in supply valued at approximately ₹20 Crore. The company reported no property damage.
The resumption marks the end of a four-day halt stemming from an unspecified event. This stoppage led to the delayed supply.
Akums confirmed no damage to its property, negating the need for an insurance claim. The swift return to full operational capacity is crucial for Akums to mitigate the impact of the disruption, enabling the company to begin recovering lost production and ensure supply chain continuity for its clients.
Akums Drugs & Pharmaceuticals Ltd. is a significant player in India's contract pharmaceutical manufacturing sector. The company plays a vital role in the domestic medicine supply chain, producing a substantial portion of the nation's pharmaceutical needs from its extensive facilities, primarily located in Haridwar.
With operations back to normal, Akums can now focus on recouping lost output from the four-day halt. Client supply chains are expected to normalize as production increases, allowing financial performance to move toward recovery.
A key risk is the company's ability to effectively recover the lost production volume in the coming weeks. Any significant challenges in this recovery could still affect future supply commitments and overall financial performance.
Akums operates in a competitive pharmaceutical contract manufacturing market. Key peers like Laurus Labs and Divi's Laboratories also have substantial manufacturing capabilities, and their success in managing operational continuity is closely watched by investors.
Investors will monitor Akums' progress in recouping lost production in the coming weeks. Tracking updates on operational efficiency and assessing the financial recovery trajectory in future disclosures will be important. Observing any new client supply commitments or adjustments will also be key.